Ohshiro Yuzuru, Takasu Nobuyuki
Second Department of Internal Medicine, University of the Ryukyus.
Nihon Rinsho. 2006 May;64(5):997-1003.
Diabetic nephropathy(DN) is the most common cause of end-stage renal disease, and is characterized by excessive accumulation of extracellular matrix in the kidney. Chronic hyperglycemia is the main cause of DN. Multiple theories have been proposed to explain the adverse effect of hyperglycemia, including an increased flux through the polyol pathway, excessive formation of advanced glycation end-products, oxidative stress, and activation of the protein kinase C (PKC) pathway. In this article, we review evidence that supports these theories, and focus our attention on the PKC theory. Therapeutic interventions to inhibit PKC are effective in reducing DN in diabetic animals. Currently, clinical trials are in progress to determine the efficacy of a PKC beta inhibitor for the treatment of diabetic complications including DN. PKC beta inhibitors may be included as a first line treatment for DN in a near future.
糖尿病肾病(DN)是终末期肾病最常见的病因,其特征是肾脏中细胞外基质过度积聚。慢性高血糖是DN的主要病因。人们提出了多种理论来解释高血糖的不良影响,包括多元醇途径通量增加、晚期糖基化终产物过度形成、氧化应激以及蛋白激酶C(PKC)途径的激活。在本文中,我们回顾了支持这些理论的证据,并将注意力集中在PKC理论上。抑制PKC的治疗干预措施在降低糖尿病动物的DN方面是有效的。目前,正在进行临床试验以确定PKCβ抑制剂治疗包括DN在内的糖尿病并发症的疗效。PKCβ抑制剂可能在不久的将来被列为DN的一线治疗药物。